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Abstract Article Info 
Introduction: Patients with nasopharyngeal carcinoma have a poor prognosis, there are several factors that cause 
it to happen, one of the existing therapeutic response has been inadequate. Expression of Epidermal Growth 
Factor Receptor (EGFR) has been used as a biological marker targeted therapy in nasopharyngeal carcinoma. 
Histopathologic subtype tumors also determine the prognosis of patients with nasopharyngeal carcinoma.  
Objective: The aim of the study to determine between the expression of epidermal growth factor receptor 
between non-keratinized differentiated and undifferentiated subtypes in nasopharyngeal carcinoma and 
correlation with their clinical stage. Study design,  Cross-sectional comparative study. Place and duration study, 
Department of Otorhinolaryngology, Department of Pathology Anatomy in Dr. M. Djamil Hospital, Padang and 
Department of Pathology Anatomy in Gajah Mada University, between May 2015 until October 2015 
Method: There were 36 samples paraffin blocks of nasopharyngeal carcinoma biopsy, respectively 18 paraffin 
blocks are non-keratinized differentiated and 18 non-keratinized undifferentiated nasopharyngeal carcinoma 
subtypes. Each sample examined EGFR expression by immunohistochemical staining methods. 
Result: There were positive EGFR expression results in all sample as 69.4%. Expression of EGFR positive non-
keratinized differentiated subtypes in nasopharyngeal carcinoma as 77.8% and undifferentiated subtype as 
61.6%. There are no significant differences of EGFR expression between non keratinized differentiated and 
undifferentiated subtypes nasopharyngeal carcinoma (p>0.05). There are no significant differences of EGFR 
expression between new and advanced stage nasopharyngeal carcinoma (p>0.05). 
Conclusion: There were no significant differences of EGFR expression between non-keratinized differentiated 
and non-keratinized undifferentiated subtypes in nasopharyngeal carcinoma. Analysis of the study also showed 
no significant differences of EGFR expression based on the clinical stage nasopharyngeal carcinoma. 
 
Keywords:  
Nasopharyngeal carcinoma, non-keratinized 
differentiated, non-keratinized undifferentiated, 
epidermal growth factor receptor 
*Corresponding author:  
Address: Jl. Perintis Kemerdekaan, Sawahan Tim, 
Kec. Padang Tim, Kota Padang, Sumatera Barat 
25171, Indonesia 
e-mail address: histawara@gmail.com 
 
1. INTRODUCTION 
Nasopharyngeal carcinoma (NPC) is a malignant tumor from 
nasopharyngeal epithelium. The etiology of NPC is multifactorial, ethnic 
and geographical factors influence the risk of disease [1]. The etiology of 
nasopharyngeal carcinoma associated with the Epstein Barr virus infection 
factors, genetic and environmental [2,3]. 
Epidemiology of NPC can be found in all countries where the incidence 
is highest in southern China, especially in the province of Guangdong [4]. 
Incidence in Guangdong province in men reach 20-50 per 100,000 
population/year [1]. NPC is found in other countries and certain in ethnic 
groups such as Chinese, Southeast Asia, and North Africa [5].  
In 2005, WHO classified the NPC into 3 subtypes: 1) Keratinized squamous 
cell carcinoma, 2) Non-keratinized differentiated and undifferentiated squamous 
cell carcinoma, 3) Basaloid squamous cell carcinoma [6]. Keratinized squamous 
cell carcinoma subtypes are rare in endemic areas, otherwise, non-keratinized 
squamous cell carcinoma subtype frequent in endemic areas and is closely linked 
with infections of Epstein Barr Virus (EBV) [7-9]. 
One of the most important elements factors to study the behavior of biological 
NPC is to understand the signaling pathways that are formed at the level of 
intracellular. There are several signaling pathways of NPC, one is the Epidermal 
Growth Factor Receptor (EGFR). EGFR is a receptor tyrosine kinase that is 
frequently expressed in the epithelial tumor. Activation of EGFR (phosphorylated 
EGFR (pEGFR)) is stimulated by several different signal transduction pathways 
such as Rat sarcoma (Ras)/Mitogen Activated Protein Kinase (MAPK), 
Phosphatidylinositol-3 Kinase (PI3K)/Act pathway, Phospholipase-Cγ 
(PLCγ)/PLC protein kinase C pathway, Signal Transducer and Activators of 
Transcription Pathway (STAT) and Src (Sarcoma) Kinase Pathway.  Transduction 
pathways activated by pEGFR play an important role in several cell processes, such 
as cell proliferation, cell differentiation, adhesion, migration and apoptos[7].              
EGFR expression was also associated with clinical stage of the tumor such as tumor 
size, lymph node involvement and distant metastasis that readvanced with 
prognosis [10].  In the last two decades, EGFR receptors as therapeutic targets in 
cancer therapy with several forms of anti-EGFR. Some studies try to learn and 
understand the mechanisms of activation and function of this receptor, which can 
be used as an anti-EGFR targeted therapy in NPC [10]. 
2. MATERIAL AND METHODS 
The study included 36 samples blocks paraffin of nasopharyngeal carcinoma 
biopsy that examined EGFR expression by immunohistochemical staining method, 
consisting of 18 samples with non-keratinized differentiated and 18 samples 
undifferentiated NPC subtypes. Methods study is a cross-sectional comparative study. 
Place and duration study is Department of Otorhinolaryngology and Pathology 
Anatomy at Dr. M. Djamil Hospital, Padang and Department of Pathology Anatomy 
at Gajah Mada University, Yogyakarta between May 2015 and October 2015.  
Immunohistochemical staining: Paraffin blocks were cut with a 
thickness of 4-6 microns then placed on a slide. The slide was carried out 
deparaffination and rehydration process and antigen retrieval. The slide was 
giving 0.3% H2O2 (in distilled water) for 30 minutes at room temperature. 
Wash slides with distilled water and PBS, incubation in 1% normal serum 
for 30 minutes at room temperature. Incubation with anti-EGFR antibody 
dilution of 1:50 at room temperature for 120 minutes. Wash slides with PBS 
3 times. Incubation in biotin-labeled secondary antibody for 30-60 minutes. 
Incubate slides in streptavidin complex for 60 minutes. Wash slides with 
PBS 3 times, each for 5 minutes. Make a fresh solution of 1 ml of distilled 
water+2 drops of buffer DAB DAB+1 drop of liquid 20 minutes before use. 
Slide gives a drop of fresh solution for 5-10 minutes. Counterstain with 
hematoksisilin, dehydration in alcohol and enter into xylene 2 times, each 
10 minutes, slide cover with a deck glass.  
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Expression of EGFR with immunohistochemical staining methods was 
read an analysis by one person from the Department of Pathology Anatomy, 
Gajah Mada University, Yogyakarta. Data were analyzed using the            
Chi-Square test and considered statistically significant if p<0.05. 
3. RESULT 
Table 1. Differences frequency based on EGFR expression between             
non-keratinized differentiated  and undifferentiated subtypes in 
nasopharyngeal carcinoma 
Non-Keratinized 
Subtype 
EGFR 
Total 
f (%) 
P  Negative 
f (%) 
Positive 
f (%) 
Differentiated 4 (22.2) 14 (77.8) 18 (100.0) 
0.469 
Undifferentiated 7 (38.9) 11 (61.1) 18 (100.0) 
Total 11(30.6) 25 (69.4) 36 (100.0)  
 
Table 2. Differences frequency based on EGFR expression between 
newly and advanced stage nasopharyngeal carcinoma 
Stage 
EGFR 
Total 
f (%) 
P  Negative 
f (%) 
Positive 
f (%) 
Newly Stage (I+II) 0 (0.0) 1 (100.0) 1 (100.0) 
1.000 
Advanced Stage (III+IV) 11 (31.4) 24 (68.6) 35 (100.0) 
Total 11 (30.6) 25 (69.4) 36 (100.0)  
4. DISCUSSION 
The expression of EGFR in non-keratinized differentiated subtypes as 77.8% 
compared with undifferentiated as 61.6%. There was no significant difference 
between non-keratinized differentiated and undifferentiated NPC subtypes with a 
value of p=0.469 (table 1) Huang et al [12] did not found a significant correlation 
between these subtypes. Huang et al. found in non-keratinized differentiated 45% 
and undifferentiated 55%. On immunohistochemical examination, there are two 
factors that affect the EGFR expression that is a preanalytic and analytic factor. The 
difference in sample tissue tumor (frozen sample tissue tumor or sample tissue 
tumor in blocks paraffin), type of fixation, large and tissue cutting techniques and 
time fixation will affect the results of the examination [13]. 
In this study, the long duration of sample tissue NPC has no effect on the results 
of EGFR expression. Zhang et al., in the retrospective study period 2005-2009, 
found 10 samples of a total of 96 samples with negative EGFR expression [14]. 
Zhang’s study concludes the long duration of sample tissue tumor does not affect 
the results of EGFR expression. Same with Huang et al study which collecting 170 
paraffin blocks of NPC sample biopsy began the period 1996-1999 [10].  
Negative false of EGFR expression could be caused by the type of fixative 
solution. The recommended fixation solution is 10% buffered formalin solution, 
while fixation in this study is a usual formalin solution. Late fixation and 
excessive fixation may also cause loss of staining reaction [13, 15]. Analytic 
factor is sample tissue processed to be ready preparation and interpreted by 
pathological experts. Methods dilution/dilution, temperature, time of incubation, 
the use of primary antibodies and others will affect the EGFR expression. 
The expression of EGFR in newly stage as 100%, while in the advanced stage 
as 68.6%. Based on statistics, no significant difference between the two groups 
stages with p=1.000 (table 2). There are several studies that reported the differences 
of EGFR expression based on the clinical stage of NPC, tumor size and node 
metastasis. Huang et al [10]  found that are no significant differences between stage 
I+ II as 42% and stage III+IV as 58% with p=0.10. Huang et al. also found no 
significant correlation between size of the T (Tumor) and N (Node) with a p-value 
of 0.18 and 0.15 respectively. 
In contrast with Zhang et al [14], there were significant differences in EGFR 
expression (p=0.001) between the newly stage 66% and advanced stage 96%. 
Zhang also found significant differences in EGFR expression base on the tumor 
size (p=0.005), although there are no significant differences (p=0.28) based on 
lymph node metastasis. 
5. CONCLUSION 
In conclusion, a number of EGFR positive expression in non-keratinized 
differentiated subtype nasopharyngeal carcinoma greater than undifferentiated 
subtypes. There was no significant differential expression of EGFR between non-
keratinized differentiated and undifferentiated NPC subtypes. Statistic analysis 
of the study also showed no significant differences of EGFR expression based on 
the clinical stage nasopharyngeal carcinoma. 
ACKNOWLEDGMENTS 
Special thank to Department of Otorhinolaryngology, Pathology Anatomy 
and Medical Records at Dr. M. Djamil Hospital, Padang and Department of 
Pathology Anatomy at Gajah Mada University, Yogyakarta that contribute help 
collect data and sample in this research. The author also would like to thank 
Research and Scientific Activity Institution Medical Faculty of Andalas 
University, Padang which has provided funding of this research. 
REFERENCE 
[1] Ma J, Cao S. The epidemiology of nasopharyngeal carcinoma.  
Nasopharyngeal Cancer: Springer; 2010. p. 1-7. 
[2] Turkoz FP, Celenkoglu G, Dogu GG, Kalender ME, Coskun U, Alkis N, et 
al. Risk factors of nasopharyngeal carcinoma in Turkey-an epidemiological 
survey of the Anatolian Society of Medical Oncology. Asian Pac J Cancer 
Prev. 2011;12(11):3017-21. 
[3] Ekburanawat W, Ekpanyaskul C, Brennan P, Kanka C, Tepsuwan K, 
Temiyastith S, et al. Evaluation of non-viral risk factors for nasopharyngeal 
carcinoma in Thailand: results from a case-control study. Asian Pac J 
Cancer Prev. 2010;11(4):929-32. 
[4] Huang Y-J, Zhang B-B, Ma N, Murata M, Tang A-z, Huang G-W. Nitrative 
and oxidative DNA damage as potential survival biomarkers for 
nasopharyngeal carcinoma. Medical Oncology. 2011;28(1):377-84. 
[5] Thompson LD. Malignant neoplasms of the nasal cavity, paranasal sinuses, 
and nasopharynx.  Head and Neck Pathology: Elsevier; 2013. p. 55-106. 
[6] Guo X, Johnson RC, Deng H, Liao J, Guan L, Nelson GW, et al. Evaluation 
of nonviral risk factors for nasopharyngeal carcinoma in a high‐risk 
population of Southern China. International journal of cancer. 
2009;124(12):2942-7. 
[7] Tulalamba W, Janvilisri T. Nasopharyngeal carcinoma signaling 
pathway: an update on molecular biomarkers. International journal of 
cell biology. 2012;2012. 
[8] Rahman S, Subroto H, Novianti D. Clinical Presentation of 
Nasopharyngeal Carcinoma in West Sumatra, Indonesia. E Poster in 
International Federation of Otorhinolaryngolocal Societies (IFOS) World 
Congress, Seoul-Korea, 1-5 Juni 2013 
[9] Prabowo I, Juliyanto A, Setiamika A. EGFR Expression in 
Nasopharyngeal Carcinoma (Undifferentiated Carcinoma) type III WHO  
in Moewardi Hospital, Surakarta. IFHNOS 2014, New York, USA. 
[10] Zeng M-S, Zeng Y-X. Pathogenesis and etiology of nasopharyngeal 
carcinoma.  Nasopharyngeal Cancer: Springer; 2010. p. 9-25. 
[11] Wei WI, Kwong DLW. Current Management Strategy of Nasopharyngeal 
Carcinoma. Clin Exp Otorhinolaryngol 2010;3(1):1-12 
[12] Huang T-L, Li C-F, Huang H-Y, Fang F-M. Correlations between 
expression of epidermal growth factor receptor (EGFR), phosphorylated 
EGFR, cyclooxygenase-2 and clinicopathological variables and treatment 
outcomes in nasopharyngeal carcinomas. Chang Gung Med J. 
2010;33(6):619-27. 
[13] Kumar GL, Rudbeck L. Education guide: immunohistochemical staining 
methods: pathology: Dako North America; 2009. 
[14] Zhang P, Wu SK, Wang Y, Fan ZX, Li CR, Feng M, et al. p53, MDM2, 
eIF4E and EGFR expression in nasopharyngeal carcinoma and their 
correlation with clinicopathological characteristics and prognosis: A 
retrospective study. Oncology letters. 2015;9(1):113-8. 
[15] Taylor CR, Shi S-R, Barr N, Wu N. Techniques of immunohistochemistry: 
principles, pitfalls, and standardization. Diagnostic immunohistochemistry. 
2013;2:1-42. 
 
